CORDIS
EU research results

CORDIS

English EN

Predictive Genomic Biomarkers Methods for Combination Bevacizumab (Avastin) Therapy in Metastatic Colorectal Cancer

Project information

Grant agreement ID: 278981

Status

Closed project

  • Start date

    1 February 2012

  • End date

    31 January 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 993 254,67

  • EU contribution

    € 5 999 155,75

Coordinated by:

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland

Objective

In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerging data now indicates that bvz fails to produce an enduring clinical response in a high proportion of patients. Delivery of the drug as part of a combination treatment regimen in mCRC elicits transitory improvements in the form of tumour stasis or shrinkage. Inevitably however, the tumours begin to re-grow and the disease progresses. It is now universally agreed that the future use of bvz in mCRC (and other cancers) is likely to be greatly influenced by the availability of predictive biomarkers to allow selection of patients who will attain the greatest benefit. The ANGIOPREDICT paradigm relies on a modular platform for the integrated discovery and validation of predictive pharmacogenomic biomarkers for combination bvz therapy in mCRC. Through initiation of a multi-centre clinical trial, early discovery findings will be validated for markers of Intrinsic Resistance to therapy. Parallel optimization of companion in vitro diagnostic tests (IVDs) through exploitation of proven SME development and validation strategies will ensure a cross-sectoral benefit to the cancer patient, prescribing physician and more broadly, across European and global public health networks. Crucially, leading SME partners will expand business portfolios into a well-defined market, progress novel intellectual property and access several in-licensing opportunities. ANGIOPREDICT uniquely unites world-class molecular diagnostic biomarker discovery SMEs with leading clinical and academic entities to identify a new generation of individualized methods for predicting response to combination bvz therapy.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND

Address

Saint Stephen'S Green 123
2 Dublin

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 199 280

Administrative Contact

Annette Byrne (Dr.)

Participants (10)

VIB VZW

Belgium

EU Contribution

€ 677 500

EPIGENOMICS AG

Germany

EU Contribution

€ 794 625

SOMANTIX BV

Netherlands

EU Contribution

€ 587 800

ONCOMARK LIMITED

Ireland

EU Contribution

€ 697 800

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

Netherlands

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 541 950,75

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 634 800

IRISH CLINICAL ONCOLOGY RESEARCH GROUP LIMITED LBG

Ireland

EU Contribution

€ 277 200

PINTAIL LTD

Ireland

EU Contribution

€ 152 000

STICHTING VU

Netherlands

EU Contribution

€ 436 200

Project information

Grant agreement ID: 278981

Status

Closed project

  • Start date

    1 February 2012

  • End date

    31 January 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 993 254,67

  • EU contribution

    € 5 999 155,75

Coordinated by:

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland